What is REVOLADE?
REVOLADE is a thrombopoietin receptor agonist or TPO-RA with a targeted mechanism of action that increases platelet production without compromising the immune system1,2
REVOLADE is a once-daily film-coated (FCT) for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments. Revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments.1
What can REVOLADE offer your ITP patients?
Platelet control without immunosuppression1,2
Across 5 clinical trials3–7
In over 5000 global subjects8*
10 years of real-world
Choose REVOLADE for your ITP patients with confidence1–8
FCT, film-coated tablet; ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.
*A total of 5541 subjects have been exposed to REVOLADE since the development international birthdate in October of 2004.8
REVOLADE Summary of Product Characteristics.
Kuter D. Int J Hematol. 2013;98:10–23.
Wong R, et al. Blood. 2017;130:2527–2536.
Cheng G, et al. Lancet. 2011;377:393–402.
Bussel J, et al. Br J Haematol. 2013;160:538–546.
Bussel J, et al. Lancet. 2015;2:315–325.
Grainger J, et al. Lancet. 2015;386:1649–1658.
Data on file REVDOFPATIENTYEARS.